Cayman, Akadeum to revolutionize cell isolation for cell and gene therapy

Cayman Chemical, a global leader in life science research tools, has announced a strategic distribution partnership with Akadeum Life Sciences, the innovator behind next-generation buoyancy-based cell separation technology. This collaboration will expand global access to Akadeum’s cutting-edge microbubble cell isolation kits, providing researchers with powerful new tools to accelerate the development of cell and gene therapies.

Manufactured at Akadeum’s headquarters in Ann Arbor, Michigan, the company’s microbubble-based technology addresses long-standing challenges in isolating pure, viable cell populations. Unlike traditional methods that can be harsh and time-consuming, Akadeum’s platform enables faster, gentler separation without compromising cell health—an essential advantage in today’s demanding therapeutic research environments.

The integration of Akadeum’s products into Cayman’s robust distribution network brings this innovative solution to a wider audience of scientists working to advance breakthroughs in immunology, regenerative medicine, oncology, and beyond. With simple protocols and high performance, these kits easily fit into existing workflows while delivering exceptional cell purity, recovery, and viability.

Brandon McNaughton, Ph.D., CEO and Founder of Akadeum Life Sciences, emphasized the impact of the partnership: “Cayman’s strong global presence and reputation make them the ideal partner to bring our microbubble technology to more researchers. Together, we’re providing a smarter, more effective way to isolate cells, supporting better outcomes in cell and gene therapy development.”

This partnership reflects Cayman Chemical’s ongoing commitment to providing researchers with state-of-the-art tools that drive innovation across the life sciences. By aligning with pioneering companies like Akadeum, Cayman continues to support the global scientific community with trusted, high-performance solutions that enable discovery.